Journal Mobile Options
Table of Contents
Vol. 9, No. 4, 2002
Issue release date: July–August 2002
J Biomed Sci 2002;9:365–370

A C597→A Polymorphism in the Norrie Disease Gene Is Associated with Advanced Retinopathy of Prematurity in Premature Kuwaiti Infants

Haider M.Z. · Devarajan L.V. · Al-Essa M. · Kumar H.
aPaediatrics Department, Faculty of Medicine, Kuwait University, bNeonatal Unit, Maternity Hospital, cOphthalmology Department, Ibn Sina Hospital, Kuwait

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Retinopathy of prematurity (ROP) is a retinal vascular disease which occurs in infants with a short gestational age and low birth weight and may lead to retinal detachment and blindness. In some premature infants, ROP progresses to advanced stages despite rigorous intervention, but in the majority, it spontaneously regresses before the threshold stage. Genetic factors, e.g. mutations in the Norrie disease (ND) gene, have been implicated in determining the progression of ROP to advanced stages. We have identified a novel C597A polymorphism of the ND gene; we screened this and another mutation in the ND gene, C110G, in 210 premature Kuwaiti infants using PCR-RFLP, DNA sequence analysis and DNA enzyme immunoassay hybridization to investigate their association with advanced-stage ROP. In this cohort of premature Kuwaiti newborns, 115 of 210 babies had no eye problems and served as controls, while 95 were found to have ROP. In 71 of the 95 ROP cases, the disease spontaneously regressed at or before stage 3, while in 24 of 95 ROP cases, the disease progressed to advanced stages 4 or 5. The incidence of the AA genotype of the C597A polymorphism was considerably higher in advanced-stage ROP cases (83.3%) compared to spontaneously regressing ROP cases (0%) and the normal controls (10.4%) (p < 0.0001). For the other genotypes, no significant difference was detected between the controls and ROP cases. In the case of the C110G mutation in the ND gene, no significant differences were detected between the controls and ROP cases, and the majority of subjects had a CC genotype in all three groups.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Arnold RW, Kesler K, Avila E. Susceptibility to retinopathy of prematurity in Alaskan Natives. J Pediatr Ophthalmol Strabismus 31:192–194;1994.
  2. Arroe M, Peitersen B. Retinopathy of prematurity: Review of a seven-year period in a Danish neonatal intensive care unit. Acta Paediatr 83:501–505;1994.

    External Resources

  3. Berger W. Molecular dissection of Norrie disease. Acta Anat (Basel) 162:95–100;1998.
  4. Berger W, Meindl A, Van de Pol TJR, Cremer FPM, Ropers HH, Doerner C, Monaco A, Bergen AAB, Lebo R, Warburg M, Zergollen L, Lorenz B, Gal A, Bleeker-Wagemakers EMT. Isolation of a candidate gene for Norrie disease by positional cloning. Nat Genet 1:199–203;1992.
  5. Bossi E, Koerner F. Retinopathy of prematurity. Intensive Care Med 21:241–246;1995.
  6. Chen ZY, Battinelli EM, Hendriks RW. Norrie disease gene: Characterization of deletions and possible function. Genomics 16:533–535;1993.
  7. Chen ZY, Battinelli EM, Fielder A, Bundey S, Sims K, Breakefield XO, Craig IW. A mutation in the Norrie disease gene (NDP) associated with X-linked familial exudative vitreoretinopathy. Nat Genet 5:180–183;1993.

    External Resources

  8. Cryotherapy for Retinopathy of Prematurity Cooperative Group. The natural ocular outcome of premature birth and retinopathy: Status at 1 year. Arch Ophthalmol 112:903–912;1994.
  9. Fuchs S, Kellner U, Wedemann H, Gal A. Missense mutation (Arg121Trp) in the Norrie disease gene associated with X-linked exudative vitreoretinopathy. Hum Mutat 6:257–259;1995.
  10. Haider MZ, Devarajan LV, Al-Essa M, Srivastva BS, Kumar H, Azad R, Rashwan N. Missense mutations in Norrie disease gene are not associated with advanced stages of retinopathy of prematurity in Kuwaiti Arabs. Biol Neonate 77:88–91;2000.
  11. Haider MZ, Devarajan LV, Al-Essa M, Srivastva BS, Kumar H, Azad R, Rashwan N. Retinopathy of prematurity: Mutations in the Norrie disease gene and the risk of progression to advanced stages. Pediatr Int 43:120–123;2001.

    External Resources

  12. Kretzer FL, McPherson AR, Hittner HM. An interpretation of retinopathy of prematurity in terms of spindle cells: Relationship to vitamin E prophylaxis and cryotherapy. Graefes Arch Clin Exp Ophthalmol 244:205–214;1986.
  13. Meindl A, Berger W, Meitinger T, Van de Pol TJR, Achatz H, Doerner C, Haasemann M, Hellebrand H, Gal A, Cremers F, Ropers HH. Norrie disease is caused by mutations in an extracellular protein resembling C-terminal globular domain of mucins. Nat Genet 2:139–143;1992.

    External Resources

  14. Meindl A, Lorenz B, Achatz H, Hellebrand H, Schmitz-Valckenberg P, Meitinger T. Missense mutations in the NDP gene in patients with a less severe course of Norrie disease. Hum Mol Genet 4:489–490;1995.

    External Resources

  15. Meitinger T, Meindl A, Bork P, Rost B, Sander C, Haasemann M, Murken J. Molecular modelling of the Norrie disease protein predicts a cystine knot growth factor tertiary structure. Nat Genet 5:376–380;1993.

    External Resources

  16. Mintz-Hittner H, Ferrell RE, Sims KB, Fernandez KM, Gemmell BS, Satriano DR, Caster J, Kretzer FL. Peripheral retinopathy in offspring of carriers of Norrie disease gene mutations. Ophthalmology 103:2128–2134;1996.
  17. Ng YK, Fielder AR, Shaw DE, Levene MI. Epidemiology of retinopathy of prematurity. Lancet ii:1235–1238;1988.
  18. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, Tung B. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 98:1628–1640;1991.
  19. Reisner SH, Amir I, Shohat M, Krikler R, Nissenkorn I, Ben-Sira I. Retinopathy of prematurity: Incidence and treatment. Arch Dis Child 60:698–701;1985.

    External Resources

  20. Shastry BS. Identification of a recurrent missense mutation in the Norrie disease gene associated with a simplex case of exudative vitreoretinopathy. Biochem Biophys Res Commun 246:35–38;1998.
  21. Shastry BS, Pendergast SD, Hartzer MK, Liu X, Trese MT. Identification of missense mutations in the Norrie disease gene associated with advanced retinopathy of prematurity. Arch Ophthalmol 115:651–655;1997.
  22. The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol 102:1130–1134;1984.
  23. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. 2. The classification of retinal detachment. Arch Ophthalmol 105:906–912;1987.

    External Resources

  24. Torrente I, Mangino M, Gennarelli M, Novelli G, Giannotti A, Vadala P, Dallapiccola B. Two new missense mutations (A105T and C110G) in the Norrin gene in two Italian families with Norrie disease and familial exudative vitreoretinopathy. Am J Med Genet 72:242–244;1997.
  25. Wong F, Goldberg MF, Hao Y. Identification of a nonsense mutation at codon 128 of the Norrie’s disease gene in a male infant. Arch Ophthalmol 111:1553–1557;1993.

    External Resources

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50